
Commentary|Videos|June 1, 2025
ASCO 2025: Top Data Highlights from 6/1
Author(s)Yan Leyfman, MD, Chandler Park, MD, MSc, FACP
Fact checked by: Kristi Rosa
MedNews Week hosts speak with 5 key opinion leaders at ASCO 2025 about the top data highlights of the day.
Advertisement
On the Clock is a dynamic video series from MedNews Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting. In each episode, key opinion leaders share the data they’re most excited about—highlighting the studies, trends, and breakthroughs that could shape clinical practice.
In this episode, hosts Chandler Park, MD, FACP, and Yan Leyfman, MD, spoke with the following key opinion leaders:
- Manmeet Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute
- Michael Wang, MD, of The University of Texas MD Anderson Cancer Center
- Jason Westin, MD, of The University of Texas MD Anderson Cancer Center
- Andrea Necchi, MD, of San Raffaele Hospital and Scientific Institute
- Vivek Patel, MD of Vanderbilt Health
Advertisement
Related to this article

Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/4/2026
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
5






